Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195322 | 0.97 | EGLN1 (0.44) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6199600 | 0.92 | EGLN1 (0.45) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6199742 | 0.88 | EGLN1 (0.51) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6199161 | 0.84 | EGLN1 (0.47) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6199118 | 0.84 | EGLN1 (0.47) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6196111 | 0.84 | EGLN1 (0.47) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6198892 | 0.84 | NR3C1 (0.48) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6201550 | 0.82 | NR3C1 (0.51) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6198157 | 0.82 | EGLN1 (0.55) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 | |
| SCHEMBL6200398 | 0.82 | EGLN1 (0.44) | EGLN1CYP1A2CYP2C9HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042295-B1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | claimed |
| WO-2004019932-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1042295-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-11 | — | — | EP | claimed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | claimed |
| WO-1999032450-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-01 | — | — | WO | claimed |
| EP-1042295-B1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | disclosed |
| WO-2004019932-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1042295-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| WO-1999032450-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | EGLN1 1974/4885CYP1A2 3335/4885CYP2C9 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.